Clinical Trials Logo

Advanced Solid Cancer clinical trials

View clinical trials related to Advanced Solid Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03884517 Terminated - Clinical trials for Advanced Solid Cancer

Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer

Start date: March 15, 2019
Phase: Phase 1
Study type: Interventional

The trial is divided into three periods. Dosing will be the first day of each cycle, 21 days per cycle. The first period is the day of first study drug delivery until the 21st day, that is, the first treatment cycle. The DLT observation, exploration of MTD, safety of single administration, tolerance and pharmacokinetics, immunity Original research will happen during this period. The second period is a 2-8 dosing cycle, with multiple doses of tolerance, pharmacokinetics, immunogenicity studies, and preliminary efficacy evaluations. After a 2-4 cycle study, patients with good tolerance and no tumor progression will continue to the 5-8 cycle dosing study. The third period is to expand the study. After exploring the MTD, the investigator and the sponsor can discuss to extend another 10-30 cases in a safe and effective dose group to further study the effectiveness and safety of BAT8003 and its pharmacokinetics.

NCT ID: NCT01416623 Terminated - Clinical trials for Advanced Solid Cancer

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Start date: September 2010
Phase: Phase 1
Study type: Interventional

Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies